OncoMatch/Clinical Trials/NCT05489211
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Is NCT05489211 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for endometrial cancer.
Treatment: Datopotamab deruxtecan (Dato-DXd) · Capecitabine · 5-Fluorouracil · Volrustomig · Carboplatin · Bevacizumab · Rilvegostomig · Prednisone/ prednisolone · Cisplatin — TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Endometrial Cancer
Gastric Cancer
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Urothelial Carcinoma
Cholangiocarcinoma
Disease stage
Metastatic disease required
Documented advanced or metastatic malignancy
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: TROP2-directed therapy
Prior treatment with TROP2-directed therapies
Cannot have received: antibody-drug conjugate
Exception: with deruxtecan payload
Prior treatment with ... other antibody-drug conjugate (ADCs) with deruxtecan payload
Lab requirements
Blood counts
Adequate bone marrow reserve and organ function
Kidney function
Adequate bone marrow reserve and organ function
Liver function
Adequate bone marrow reserve and organ function
Adequate bone marrow reserve and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Los Angeles, California
- Research Site · San Diego, California
- Research Site · Santa Rosa, California
- Research Site · Muncie, Indiana
- Research Site · Kansas City, Kansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05489211 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior TROP2-directed therapy, antibody-drug conjugate disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 130 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages